Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 14, 2012

View Archived Issues

Scientists disclose new CD27-targeted candidate immunotherapeutics

GlaxoSmithKline presents highlights of 2011

Novel epithelial sodium channel blockers identified at Novartis

Metal chelators protect against proteins linked to neurodegenerative disorders

New antimicrobials specifically target NAD+-dependent DNA ligases

Antisense Therapeutics provides update on second-generation product

Neuropeptide W/neuropeptide B NPBW1 receptor antagonists described

New candidate cancer immunotherapies developed in France

Merck & Co. reports novel antibacterial immunotherapies

Novel products for hemophilia designed at Novo Nordisk

New bile acid GPBA receptor agonists developed at Roche

U.S. university patents new microRNA-based cancer therapies

Roche reports novel kinase inhibitors

U.S. scientists identify first inhibitors of menin/MLL fusion protein interaction

Alexza Pharmaceuticals receives first feedback on Adasuve MAA

Valeant Pharmaceuticals announces planned acquisition

BioDiem grants exclusive license for LAIV vaccine technology

Advanced Cell Technology treats third patient in phase I/II stem cell study

Celsion kicks off enrollment in ThermoDox trial

Phase III StemEx study is fully enrolled

Karo Bio discontinues development of eprotirome

Amylin Pharmaceuticals launches Bydureon in U.S.

CPP-115 receives European orphan drug status

FDA approves first preservative-free tafluprost ophthalmic solution

FDA grants priority review to Truvada sNDA

Cyclacel reports interim phase II data on sapacitabine in MDS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 29, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...